

The three-dimensional structure of thymidine kinase from Herpes simplex virus type 1

Klemens Wild^a, Thomas Bohner^b, André Aubry^c, Gerd Folkers^b, Georg E. Schulz^{a,*}

^a*Institut für Organische Chemie und Biochemie, Albert-Ludwigs-Universität, Albertstr. 21, Freiburg im Breisgau, Germany*

^b*Department Pharmazie, Eidgenössische Technische Hochschule, Zürich, Switzerland*

^c*LCM3B, Université Henri Poincaré, Nancy I, Vandoeuvre Cedex, France*

Received 26 May 1995; revised version received 8 June 1995

Abstract Recombinant thymidine kinase from Herpes simplex virus type 1 (ATP:thymidine 5'-phosphotransferase; EC 2.7.1.21), an enzyme of therapeutic importance, was purified and crystallized in an N-terminally truncated but still fully active form. The three-dimensional structure was solved by X-ray diffraction analysis at 3.0 Å resolution using isomorphous replacement. The chain fold is presented together with the bound substrates thymidine and ATP. Three chain segments at the surface could not be located. The chain fold, the location of the substrates and presumably also the catalytic mechanism resemble the well-known adenylate kinases.

Key words: Thymidine kinase; Herpes simplex virus; X-Ray analysis; Phosphoryl transfer; Chain fold

1. Introduction

Thymidine kinase (TK) is the key enzyme in the pyrimidine salvage pathway. Whereas the mammalian cytosolic isozyme catalyzes the transfer of the γ -phosphate from ATP·Mg²⁺ to thymidine to produce thymidine monophosphate (dTMP), the virus encoded isozyme repeats this step yielding thymidine diphosphate (dTDP) [1,2]. Moreover, host TK accepts only pyrimidines, whereas viral TK also accepts purines, and even those carrying an acyclic ribose analogue such as the prodrugs acyclovir or gancyclovir. In virus-infected cells these prodrugs are activated to their triphosphates and incorporated into the viral DNA resulting in chain termination [3]. As the activation is catalyzed nearly exclusively by the viral TK, only infected cells are hit [4]. Moreover, TK is used in the so-called 'virally directed enzyme prodrug therapy', where the gene for viral TK is introduced to tumor cells followed by administration of gancyclovir. The viral TK renders the proliferating cells susceptible to this treatment by transforming gancyclovir into a cytotoxic drug.

The structure of the viral TK is expected to provide a basis for rational design of more efficient substrates, inhibitors or enzymes for severe Herpes viral infections and for the gene therapy approach on tumors. Here, we describe the crystal structure of a recombinant viral TK from Herpes simplex virus type 1 (HSV1) expressed as fusion protein in *E. coli*. The en-

zyme is N-terminally truncated by 33 residues, but still fully active. It is dimeric with $M_r = 2 \times 37,129$.

2. Materials and methods

2.1. Materials

Enzymes used in molecular cloning were obtained from Boehringer-Mannheim. Thrombin, glutathione-agarose, ATP-agarose and other chemicals were purchased from Sigma. The plasmid pGEX2T was purchased from Pharmacia. The plasmid pBR322-TK containing the gene for TK from HSV1 was a gift from S. McKnight (Baltimore). *E. coli* strain 71/18 was the host for cloning procedures. The TK-deficient *E. coli* strain KY895 was used for expression of the fusion protein glutathione-S-transferase-TK.

2.2. Expression and purification

The bacterial expression vector pGEX2T-TK was constructed as described earlier [5]. Purification of the glutathione-S-transferase-TK fusion protein was carried out by glutathione affinity chromatography, thrombin cleavage followed by ATP affinity chromatography as described [2,6]. Expression and purification were monitored by SDS-PAGE using the Phast System from Pharmacia; the enzyme activity was measured as described [6]. Protein concentrations were determined according to Bradford [7] and by amino acid analysis.

2.3. Crystallization

For crystallization, we used the hanging drop method at 4°C. The purified N-terminally truncated protein started at residue position 34, where the viral TK is sensitive to thrombin cleavage. The truncation was confirmed by N-terminal sequence analysis. The enzyme was kept in a buffer containing 10 mM MOPS at pH 7.5, 1 mM EDTA, 0.1% Triton X-100, 2 mM DTT, 50 μ M thymidine and 10 mM ATP. Using a centricron the protein was concentrated to 40 mg/ml and subsequently diluted with the same buffer (but without Triton X-100 and ATP) to 5 mg/ml. The resulting protein solution was mixed in a 1:1 ratio with the crystallization buffer (40–50 mM KH₂PO₄, pH 5.5, 1 mM DTT, 50 μ M thymidine, 15–20% PEG-8000, 0.02% Na₂S₂O₃) to give a drop of 5 μ l. The reservoir contained the crystallization buffer.

Crystals appeared after 3 days and grew within 1–2 weeks to sizes of about 300 × 200 × 200 μ m³. They belong to space group I4₁ with $a = b = 83.4$ Å, $c = 156.7$ Å and one subunit of the dimeric enzyme in the asymmetric unit. At 67% the solvent content is rather high. The crystals are reasonably stable in the X-ray beam and diffract to 2.8 Å resolution under X-radiation from a rotating anode and to 2.5 Å at a synchrotron (EMBL-outstation, DESY, Hamburg). They differ from crystals of TK from HSV1 reported earlier [8].

2.4. Data collection and phase determination

Data were collected using a rotating anode (model RU200B, Rigaku) together with a multi-wire area detector (model X1000, Siemens). Data processing was with program XDS [9]. Heavy atom derivatives were produced by soaking (Table 1). The difference Pattersons of all 3 derivatives were clearly interpretable. Unfortunately, all of them were single site derivatives with mercury bound to Cys-336. The heavy atom parameters were refined with program PHASIT from the PHASES package (W. Furey, 1991; University of Pittsburgh, PA, USA) yielding an essentially single isomorphous replacement electron density map. This map was poor, but could be strongly improved by solvent-flattening using program BNDY of PHASES. The resulting map allowed us to

*Corresponding author. Fax: (49) (761) 203-5987.
E-mail: schulz@bio2.chemie.uni-freiburg.de

Abbreviations: DTT, dithiothreitol; HSV1, Herpes simplex virus type 1; PEG, polyethylene-glycol; TK, thymidine kinase.

The bottom of the active site (view of Fig. 3) includes sequence motif -F¹⁶¹-D-R-H-, which is highly conserved among




Fig. 2. Stereo-view of the current C_{α} -backbone of dimeric thymidine kinase from Herpes simplex virus type 1 with numbering and the bound substrates thymidine and ATP. The dashed lines indicate regions of low density which have not yet been modeled. The chosen orientation emphasizes the planarity of the interface. The two-fold axis runs from the lefthand side in the front to the right hand side in the rear.

the thymidine kinases [16,17]. It consists of the C-terminal end of β -strand b3 and part of the following loop. In the adenylate kinases the equivalent of Asp-162 fixes the Mg^{2+} required for catalysis via water molecules [18]. Furthermore, the change Asp-162→Asn in TK from HSV1 yields a completely inactive enzyme [19]. Arg-163 points towards the ribose of thymidine and is likely to bind the additional phosphoryl group of dTMP. A similarly located arginine in the adenylate kinases binds to the α -phosphate of AMP [12]. A natural mutation (to Gln) of the respective arginine in TK of Varicella zoster virus resulted in acyclovir resistance [20], corroborating its importance for the phosphorylation of dTMP.

In conclusion, we find that the presented preliminary structure in combination with the extensive knowledge about the distantly related adenylate kinases provides already a solid framework for understanding the catalysis of the viral TK.

Acknowledgements: We thank Dr. S. McKnight for providing us with the gene of TK from HSV1, Dr. J. Fetzer for helpful discussions about cloning and purification, and Dr. K.S. Wilson and his team for help in collecting one of the data sets with synchrotron radiation. The project was supported by the Land Baden-Württemberg.

References

- [1] Chen, M.S., Walker, J. and Prusoff, W.H. (1979) *J. Biol. Chem.* 254, 10747–10753.
- [2] Michael, M., Fetzer, J. and Folkers, G. (1994) *Eur. J. Biochem.* 226, 219–226.
- [3] Coen, M.D. (1992) *Semin. Virol.* 3, 3–12.
- [4] Elion, G.B., Furman, P.A., Fyfe, J.A., DeMiranda, P., Beauchamp, L. and Schaeffer, H.J. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5716–5720.
- [5] Fetzer, J. and Folkers, G. (1992) *Pharm. Pharmacol. Lett.* 2, 112–114.




Fig. 3. Stereo-view of the C_{α} -backbone around the active center together with the bound substrates thymidine and ATP. Presented are five polypeptide segments, all starting at the carboxy-terminal end of the parallel 5-stranded β -sheet. The segments starting at positions 52, 80, 160, 202, and 324 contain α -helices a1, a2 & a3 and part of a4, a5, a7 and part of a8, and a10, respectively. The glycine-rich loop encircles the β -phosphoryl group of ATP.

- [6] Fetzer, J., Michael, M., Bohner, T., Hofbauer, R. and Folkers, G. (1994) *Protein Exp. Purif.* 5, 432–441.
- [7] Bradford, M.M. (1976) *Anal. Biochem.* 72, 248–254.
- [8] Sanderson, M.R., Freemont, P.S., Murthy, H.M.K., Krane, J.F., Summers, W.C. and Steitz, T.A. (1988) *J. Mol. Biol.* 202, 917–919.
- [9] Kabsch, W. (1988) *J. Appl. Crystallogr.* 21, 916–924.
- [10] Schulz, G.E., Elzinga, M., Marx, F. and Schirmer, R.H. (1974) *Nature* 250, 120–123.
- [11] Dreusicke, D. and Schulz, G.E. (1986) *FEBS Lett.* 208, 301–304.
- [12] Müller, C.W. and Schulz, G.E. (1992) *J. Mol. Biol.* 224, 159–177.
- [13] Schulz, G.E. (1992) *Curr. Opin. Struct. Biol.* 2, 61–67.
- [14] Waldmann, A.S., Häusslein, E. and Milman, G. (1983) *J. Biol. Chem.* 258, 11571–11575.
- [15] Berry, M.B., Meador, B., Bilderback, T., Liang, P., Glaser, M. and Phillips, G.N.Jr. (1994) *Proteins: Struct. Funct. Genet.* 19, 183–198.
- [16] Folkers, G., Trumpp, S., Eger, K., Roth, H.J. and Schwoebel, W. (1987) *Med. Sci. Res.* 124, 137–140.
- [17] Balasubramaniam, N.K., Veerisetty, V. and Gentry, G.A. (1990) *J. Gen. Virol.* 71, 2979–2987.
- [18] Abele, U. and Schulz, G.E. (1995) *Protein Sci.* 4 (in press).
- [19] Fetzer, J., Folkers, G., Müller, I. and Keil, G.M. (1993) *Virus Genes* 7, 205–209.
- [20] Sawyer, M.H., Inchauspe, G., Biron, K.K., Waters, D.J., Straus, S.E. and Ostove, J.M. (1988) *J. Gen. Virol.* 69, 2585–2593.